<DOC>
	<DOCNO>NCT01445301</DOCNO>
	<brief_summary>This multicenter , randomize , single-blinded ( investigator 's blind ) , active-controlled ( clindamycin [ CLDM ] 1 % gel ) , parallel-group study Japanese subject acne vulgaris demonstrate efficacy GSK2585823 ( CLDM 1 % -benzoyl peroxide [ BPO ] 3 % gel ) apply twice daily 12 week . This study also evaluate safety GSK2585823 apply topically either twice daily 12 week .</brief_summary>
	<brief_title>Study STF115287 , Clinical Confirmation Study GSK2585823 Treatment Acne Vulgaris Japanese Subjects</brief_title>
	<detailed_description>Main inclusion criterion 12 45 year age , Investigator Static Global Assessment ( ISGA ) score 2 great baseline visit , 17 60 facial inflammatory lesion ( papule plus pustule ) 20 150 facial non-inflammatory lesion ( open close comedo ) , include nasal lesion . The primary objective demonstrate superiority GSK2585823 twice daily CLDM twice daily total lesion count , demonstrate non-inferiority GSK2585823 daily CLDM twice daily total lesion count . The secondary objective demonstrate non-inferiority GSK2585823 daily CLDM twice daily inflammatory lesion count , evaluate efficacy GSK2585823 twice daily compare CLDM twice daily visit . A total 800 subject enrol randomly assign one group .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Male female subject 12 45 year ( inclusive ) age good general health . Subjects must face : A ) A minimum 17 60 inflammatory lesion ( papules/pustules ) , include nasal lesion . And B ) A minimum 20 150 noninflammatory lesion ( open/closed comedo ) , include nasal lesion . An ISGA score 2 great baseline . Females childbearing potential woman le 2 year last menses must agree use contraception . The ability willingness follow study procedure attend schedule visit . The ability understand sign write informed consent form ( Written inform consent must obtain also parent guardian case subject 20 year age time give consent ) . Have nodulecystic lesion baseline . Are pregnant breastfeeding . Have history presence regional enteritis , inflammatory bowel disease ( e.g. , ulcerative colitis , pseudomembranous colitis , chronic diarrhea antibioticassociated colitis ) similar symptom . Used follow agent face within previous 2 week : Topical antibiotic ( systemic antibiotic ) ; Topical antiacne medication ( e.g. , BPO , azelaic acid , resorcinol , salicylates ) ; Abradants , facial , peel contain glycolic acid ; Masks , wash soap contain BPO , sulfacetamide sodium , salicylic acid ; Nonmild facial cleanser ( e.g. , facial scrub , cleanser contain agent antiinflammatory action ) ; Moisturizers contain retinol , salicylic acid , α βhydroxy acid ; Astringents toner ( Subjects allow enroll study , subject treatment 2 consecutive week prior start investigational product use ) . Used follow agent face perform following procedure within previous 4 week : Topical corticosteroid ( Use inhale , intraarticular , intralesional steroid facial acne acceptable ) ; Facial procedure ( chemical laser peel , microdermabrasion , blue light treatment , etc. ) . Used systemic retinoids within previous 6 month topical retinoids face within previous 6 week . Received treatment estrogen , androgen , antiandrogenic agent within previous 12 week ( Subjects treat agent 12 consecutive week prior start investigational product allow enrol long expect change dose , drug , discontinue use study ) . Used medication opinion investigator may affect clinical study evaluation study . Plan use medication report exacerbate acne ( e.g. , megadoses certain vitamin , vitamin D [ &gt; 2000 IU/day ] vitamin B12 [ &gt; 1 mg/day ] , corticosteroids* , androgen , haloperidol , halogens [ e.g. , iodide bromide ] , lithium , hydantoin , phenobarbital ) . * : except use topical corticosteroid ( e.g. , inhale , intraarticular , intralesional steroid ) facial acne . Have know hypersensitivity previous allergic reaction component investigational product . Used investigational therapy within previous 12 week , plan participate another clinical study time . Participated Japanese clinical study plan GlaxoSmithKline K.K . development investigational product acne vulgaris . Are currently abuse drug alcohol . Have significant medical history immunocompromised . People follow family member : Employees GlaxoSmithKline , contract research organization ( CRO ) site management organization ( SMO ) ; Investigators . Have condition would put subject unacceptable risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>twice daily</keyword>
	<keyword>daily</keyword>
	<keyword>CLDM 1 % -BPO 3 % gel</keyword>
	<keyword>Clindamycin ( CLDM )</keyword>
	<keyword>benzoyl peroxide ( BPO )</keyword>
	<keyword>inflammatory lesion</keyword>
	<keyword>non-inflammatory lesion</keyword>
	<keyword>acne vulgaris</keyword>
</DOC>